Cvs Health CORP 8-K filings

CVS Health announced robust second quarter 2026 results, with total revenues up 7.3% year-over-year to $106.1 billion, and raised its full-year guidance for EPS and cash flow.

CVS Health Corporation's stockholders approved the 2026 Incentive Compensation Plan and ratified the appointment of Ernst & Young LLP as independent auditor at the 2026 Annual Meeting.

CVS Health announced robust first-quarter 2026 results, with total revenues reaching $100.4 billion, a 6.2% year-over-year increase, and raised its full-year earnings and cash flow guidance.

CVS Health Corporation announced the election of John E. Gallina, former Executive Vice President and Chief Financial Officer of Elevance Health, Inc., to its Board of Directors, effective March 19, 2026.

CVS Health announced robust full-year 2025 revenues of $402.1 billion, alongside a significant goodwill impairment charge and updated 2026 cash flow guidance.

CVS Health updated its 2025 financial guidance, provided 2026 guidance, and announced a strategy to reimagine healthcare, targeting mid-teens Adjusted EPS CAGR through 2028.

CVS Health's Board of Directors has appointed President and CEO J. David Joyner as Chair, effective January 1, 2026, consolidating leadership roles.

CVS Health reported a third-quarter GAAP diluted loss per share of $3.13 due to a $5.7 billion goodwill impairment charge, despite record revenues and a raised Adjusted EPS outlook.

CVS Health's long-term care pharmacy subsidiary, Omnicare, has initiated voluntary Chapter 11 bankruptcy proceedings to address significant litigation damages and broader industry financial challenges.

CVS Health Corporation successfully issued $4 billion in senior notes across four tranches with maturities ranging from 2032 to 2065, securing approximately $3.96 billion in net proceeds.

CVS Health Corporation announced second quarter 2025 financial results showing strong revenue growth and raised full-year Adjusted EPS and cash flow guidance, despite a significant decline in GAAP earnings due to substantial litigation charges.

CVS Health held its annual meeting on May 15, 2025, and stockholders voted on director elections, auditor ratification, executive compensation, and a stockholder proposal.

CVS Health announced a 7.0% increase in total revenues for Q1 2025, driven by growth across all segments, and updated its full-year guidance.

CVS Health announced the appointment of Brian O. Newman as Executive Vice President and Chief Financial Officer and Amy L. Compton-Phillips, M.D. as Executive Vice President and Chief Medical Officer, effective in May 2025.

CVS Health's Q4 results show revenue growth but a decline in earnings, with full-year results reflecting similar trends and the company issuing its 2025 financial guidance.

CVS Health has announced the early results and pricing of its cash tender offer for various series of senior notes, with an aggregate purchase price not exceeding $1,774,423,242.62.

CVS Health Corporation has successfully issued $3 billion in junior subordinated notes, split into two series with varying interest rates and maturity dates.

CVS Health has announced the expiration and results of its cash tender offer for its 4.100% Senior Notes due 2025, with a settlement date expected on December 11, 2024.

CVS Health has announced the pricing for its cash tender offer for any and all of its 4.100% Senior Notes due in 2025.

CVS Health Corporation has successfully entered into an underwriting agreement to issue $3 billion in junior subordinated notes, split between two series with varying interest rates and maturity dates.

CVS Health has launched cash tender offers to repurchase a portion of its outstanding senior notes, including those from its subsidiary Aetna, with a total cap of $2 billion.

CVS Health has appointed four new directors to its board, including Larry Robbins of Glenview Capital Management, following a confidentiality agreement between the two entities.

CVS Health has announced the appointment of Prem Shah as Group President and Steve Nelson as President of Aetna, effective November 6, 2024.

CVS Health's third quarter results show a revenue increase but are significantly impacted by charges in the Health Care Benefits segment.

CVS Health announced the appointment of David Joyner as CEO, replacing Karen Lynch, and released preliminary Q3 2024 results including charges for premium deficiency reserves and restructuring.

CVS Health reported a 2.6% increase in second-quarter revenue but lowered its full-year earnings and cash flow guidance due to pressures in its Health Care Benefits segment.

CVS Health Corporation's stockholders approved an amendment to the 2017 Incentive Compensation Plan, increasing the number of shares available for issuance by 33.5 million, at their 2024 Annual Meeting.

CVS Health Corporation has successfully issued $5 billion in senior notes across five tranches with varying maturities and interest rates.

CVS Health Corporation has entered into an underwriting agreement to issue and sell $5 billion in aggregate principal amount of senior notes with varying maturities.

CVS Health lowered its full-year 2024 earnings and cash flow guidance due to higher than expected medical costs, particularly in its Medicare Advantage business, despite a revenue increase in the first quarter.